DEA Issues Order Against Mystery LLC: Details Classified?
Published Date: 10/21/2025
Notice
Summary
MCRGC, LLC wanted to grow marijuana but didn’t have the right licenses, a real location, or proper agreements, so the DEA said no to their application. Since MCRGC didn’t ask for a hearing or fix these issues, their request got denied for good. This means MCRGC can’t legally grow marijuana, and anyone applying must have all paperwork and approvals in place to avoid the same fate.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Denies MCRGC's Registration
The DEA denied MCRGC, LLC's application for a Certificate of Registration (Control No. W16097592E) and any pending amendments. The final Order denying the application is effective November 20, 2025, so MCRGC cannot obtain DEA registration under that application.
Documented Registration Requirements for Growers
The Agency applied criteria that applicants seeking DEA registration to grow marijuana must have a physical location DEA can inspect, possess a DEA Schedule I researcher certificate if seeking to grow for research/product development, and have a bona fide supply agreement with a registered Schedule I researcher. These criteria were cited in the record as weighing against MCRGC's application.
Failure to Request Hearing Causes Default
Under 21 CFR 1301.43, an applicant served with an Order to Show Cause must file a hearing request within 30 days of receipt or be deemed in default and have the OSC's factual allegations admitted. In this case, DEA mailed the OSC on May 7, 2024, the applicant did not timely request a hearing, and the Agency found MCRGC in default.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-19612 — Hil Rizvi, M.D.; Decision and Order
Dr. Hil Rizvi from Utah tried to get a DEA registration but got denied because he lied on his application. The DEA found he didn’t tell the truth about important questions, which risks public safety. This decision means Dr. Rizvi won’t get his registration, and the denial is final as of early 2025.
Next: 2025-19619 — National Advisory Committee on Institutional Quality and Integrity; Notice of Meeting
The National Advisory Committee on Institutional Quality and Integrity is meeting soon to talk about how schools and colleges keep their quality high. This affects students, schools, and anyone interested in education standards. They’ll discuss important updates that could change how schools get recognized, with some decisions coming soon that might impact funding and timing.